12:00 AM
 | 
Jan 28, 2013
 |  BC Week In Review  |  Company News  |  Deals

Cytos, Novartis deal

Cytos said that Novartis will terminate a 2007 deal and return to Cytos rights to smoking cessation compound NIC002. In 2009, a Phase II trial conducted...

Read the full 110 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >